Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of furosemide ointment in China. Welcome to wholesale bulk high quality furosemide ointment for sale here from our factory. Good service and reasonable price are available.
Furosemide Ointment, as a classic and potent diuretic, is administered topically through the skin. There is a tubular like ion transport system in the skin, and Furosemide can alleviate edema by inhibiting the Na-K-2Cl ⁻ co transporter in skin cells, reducing the accumulation of sodium and water in local tissue fluids. Research has shown that local application of furosemide can significantly reduce the local water content in experimental animal skin edema models. Mainly, it can dilate local blood vessels, improve microcirculation, increase local blood flow, thereby promoting the excretion of metabolic waste and nutrient supply. This effect has a positive significance for the healing of chronic venous stasis ulcers and other diseases. Because it is a drug with weak lipophilicity, its skin permeability is limited. To improve its local bioavailability, chemical penetration enhancers such as propylene glycol and oleic acid are often used, which can alter the structure of the skin's stratum corneum and increase drug penetration; Physical methods such as ion introduction, ultrasound introduction, etc. can promote transdermal absorption of drugs; Nanocarriers such as liposomes, nanoparticles, etc. can encapsulate drugs, increase skin retention and penetration depth. Research has shown that after using penetration enhancers, the skin penetration of furosemide can be increased several times, and the local blood drug concentration can be significantly increased.
Our products
Furosemide COA
Accurate delivery of furosemide ointment nano drug delivery system
Furosemide Ointment, as a classic loop diuretic, has a bioavailability of less than 50% in its oral formulation due to first pass effects, and significant gastrointestinal side effects. Although local administration can avoid systemic toxicity, traditional ointments are limited by the physical and chemical properties of the skin barrier, resulting in low drug penetration efficiency. The nano drug delivery system provides a revolutionary solution for transdermal delivery of furosemide by regulating drug release kinetics, enhancing targeting, and breaking through barrier limitations.
The complexity of the skin barrier: the biological basis for breakthroughs in nanotechnology
The "brick wall structure" of the stratum corneum and drug penetration resistance
The stratum corneum is composed of 15-20 layers of dead keratinocytes and intercellular lipids. Its natural moisturizing factor (NMF) maintains cell hydration, while the lipid bilayer composed of ceramides, cholesterol, and free fatty acids arranged in a 1:1:1 molar ratio forms a dense barrier. Experiments have shown that the complete stratum corneum has a permeability coefficient of only 10 ⁻⁷ cm/h for water-soluble drugs (such as furosemide, molecular weight 330.74Da), resulting in only 3% -5% of drugs in traditional ointments being able to penetrate the stratum corneum.
Anatomical heterogeneity of accessory channels
Although hair follicles, sweat glands, and sebaceous glands account for only 0.1% of the skin surface area, they can serve as "bypass channels" for drug penetration. Among them, the density of facial hair follicles reaches 100/cm ², while the palm only has 10/cm ², resulting in significant differences in drug penetration efficiency among different regions. Research has shown that the local concentration of furosemide formulations using hair follicle infiltration can reach 3.2 times that of traditional ointments, but the anatomical heterogeneity of accessory distribution requires formulation design to achieve site specificity.
Distribution and metabolic barrier of the dermis layer
After the drug penetrates the stratum corneum, it needs to enter the capillaries through the dermis layer with a water content of 70%. The distribution coefficient (Kp) of furosemide in the dermis is 0.25, which easily binds to tissue proteins to form a "reservoir effect", leading to drug retention. In addition, esterases and phosphatases in the dermis can degrade some drug molecules, further reducing their bioavailability.
The technological path of nano drug delivery system: from passive permeation to active regulation
Polymer nanoparticles: dual optimization of sustained release and targeting
Poly (lactic acid glycolic acid) copolymer (PLGA) nanoparticles are hydrolyzed and degraded into lactic acid and glycolic acid, achieving sustained release for 2-4 weeks. After preparing furosemide into PLGA nanoparticles, its solubility increased by 12 times, and through surface modification of folate receptor ligands, it can specifically target the highly expressed folate receptors on the surface of tumor associated fibroblasts (CAFs) (density 100-300 times that of normal cells). Preclinical studies have shown that this formulation increases drug concentration at the target site by 8.3 times, while reducing systemic exposure by 92%.
Liposomes: Intelligent Delivery Simulating Biofilms
Liposomes are composed of phospholipid bilayers that can encapsulate furosemide to mimic the structure of biological membranes. By modifying with polyethylene glycol (PEG) to prolong circulation time and surface modifying with anti vascular endothelial growth factor (VEGF) monoclonal antibodies, tumor tissue angiogenesis can be blocked. Among the 14 approved liposomal drugs worldwide, doxorubicin liposomes have tripled the therapeutic index by reducing cardiac toxicity. Similarly, in the inflammatory edema model, the local concentration of furosemide liposomes reached 5.8 times that of the free drug, and the 24-hour cumulative permeation met the therapeutic requirements.
Micro needle array: mechanical penetration and controllable release
A 500 μ m long polymethyl methacrylate (PMMA) microneedle array can create 200 μ m level microchannels within 10 seconds, increasing the penetration of furosemide by 17 times. Dissolvable microneedles are prepared by blending polyvinyl alcohol (PVA) with furosemide Ointment, and the needle body releases the drug after dissolving in the skin, avoiding the risk of residual metal microneedles. Animal experiments have shown that this technology reduces the peak time of furosemide in subcutaneous tissue from 2 hours to 15 minutes, and increases its bioavailability to 68%.
The synergistic effect of chemical penetration enhancers (CPEs)
Surfactants
Sodium dodecyl sulfate (SDS) increases the permeation flux of furosemide by 6.3 times by disrupting the lipid arrangement between keratinocytes, but its clinical application is limited by its cytotoxicity. New block copolymers, such as PEG-DTAB, shield charges through polyethylene glycol chains, reducing toxicity while maintaining a penetration enhancement efficiency of over 85%.
Terpenoids
Menthol triggers local vasodilation by activating TRPV1 channels, forming hydrogen bonds with sulfonamide groups in furosemide molecules, reducing the crystallinity of the drug by 40% and increasing its solubility by 2.5 times in the ointment matrix. This "molecular gel" effect prolongs the drug release cycle, with the duration of single dose efficacy increasing from 6 hours to 18 hours.
Enzyme responsive CPEs
Connect oleic acid with esterase sensitive peptide segments to form enzyme responsive CPE. In the inflamed area (MMP high expression), peptide degradation triggers CPE release, avoiding normal tissue stimulation. Preclinical studies have shown that this strategy increases skin survival rates from 62% to 91%, while maintaining a penetration efficiency of over 80% compared to traditional CPE.
Systemic physiological changes caused by local effects
Distribution of body fluids and regulation of blood volume
Decreased blood volume and increased venous return：Furosemide rapidly reduces extracellular fluid volume through its diuretic effect (usually taking effect within 30 minutes). The decrease in blood volume leads to a decrease in venous pressure, resulting in a reduction in the amount of blood flowing back to the right atrium, which in turn lowers the pressure in the right atrium. This change inhibits atrial natriuretic peptide (ANP) release through the Bainbridge reflex, but the potent diuretic effect of furosemide often masks this effect.
Dual regulation of left ventricular preload and afterload：Pre load reduction: A decrease in blood volume directly reduces left ventricular end diastolic volume (LVEDV), decreases the degree of myocardial fiber stretching, and thus reduces myocardial contractility (according to Frank Starling's law). This effect is crucial in the treatment of acute heart failure, as it can quickly alleviate symptoms of pulmonary congestion.
Post load reduction: Furosemide Ointment reduces peripheral vascular resistance (SVR) by dilating peripheral blood vessels (possibly by inhibiting prostaglandin degrading enzyme activity and increasing prostaglandin E2 levels). Experiments have shown that after intravenous injection of furosemide, mean arterial pressure (MAP) can decrease by 10% -15% within 15 minutes.
Electrolyte balance and acid-base balance disorder
Electrophysiological changes in myocardial cells: Hypokalemia leads to a decrease in negative resting membrane potential (depolarization) of myocardial cells, inactivation of sodium channels, slowing down the rate of action potential rise in phase 0, and reduced conductivity. This may cause arrhythmia, especially ventricular premature beats and apical torsion ventricular tachycardia.
Skeletal muscle weakness: Hypokalemia affects the release of acetylcholine at the neuromuscular junction, leading to muscle weakness and, in severe cases, respiratory muscle paralysis.
Metabolic alkalosis: Potassium ions are transferred into cells to compensate for hypokalemia, while hydrogen ion efflux increases, leading to an increase in plasma bicarbonate (HCO ∝⁻) concentration and causing metabolic alkalosis (pH>7.45).
The hyponatremia caused by furosemide (blood sodium<135mmol/L) is usually caused by dilute hyponatremia, that is, water retention exceeds sodium retention. This phenomenon is particularly common in patients with cirrhosis or heart failure, as increased secretion of antidiuretic hormone (ADH) leads to enhanced water reabsorption.
Activation of Renin Angiotensin Aldosterone System (RAAS)
Reduced blood volume and decreased glomerular afferent arteriole pressure stimulate renin secretion. Renin converts angiotensinogen into angiotensin I (Ang I), which generates angiotensin II (Ang II) under the action of angiotensin-converting enzyme (ACE).
Vasoconstriction: Ang II directly acts on vascular smooth muscle cells, causing constriction of small arteries throughout the body and increasing blood pressure.
Increased aldosterone secretion: Ang II stimulates the adrenal cortical globular zone to secrete aldosterone, which promotes the reabsorption of sodium and the excretion of potassium in the distal convoluted tubules and collecting ducts of the kidney, forming a vicious cycle of "sodium retention - potassium loss".
Sympathetic nervous system excitation: Ang II acts on the central nervous system, increases sympathetic nervous system activity, further raises blood pressure, and increases cardiac burden.
Hot Tags: furosemide ointment, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale